Altered DNA methylation is associated with aberrant stemness gene expression in early‑stage HNSCC

  • Authors:
    • Takatsugu Suzuki
    • Hiroshi Yamazaki
    • Kazufumi Honda
    • Eijitsu Ryo
    • Akihiro Kaneko
    • Yoshihide Ota
    • Taisuke Mori
  • View Affiliations

  • Published online on: August 14, 2019     https://doi.org/10.3892/ijo.2019.4857
  • Pages: 915-924
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Head and neck squamous cell carcinoma (HNSCC) is characterized by morphological and functional cellular heterogeneity, which are properties of progenitor cells, as opposed to cell alterations caused by accidental expression of stem cell‑related molecules. The expression levels of stemness molecules and their distribution in HNSCC are unclear. As regards sporadic cellular heterogeneity, methylation is an important factor for transcriptional regulation in tumors. Integrative screening analysis of mRNA expression and altered methylation status was performed with original microarrays in 12 tumor and non‑tumor pairs of oral squamous cell carcinoma (SCC) cases. From this data set, genes regulated via aberrant DNA methylation and classified proteins were validated by function clustering. Olfactomedin 4 (OLFM4), known as an intestinal stemness molecule and cell‑cell adhesion factor, was found to be highly expressed in tumors, with an mRNA expression ratio [tumor/normal (T/N)] of 40.7686 and low methylation (‑18.02%) in the promoter region. In addition, the OLFM4 expression levels increased following treatment with the demethylating agent 5‑azacytidine in two HNSCC cell lines. Furthermore, the expression levels of OLFM4 in 59 cases of early‑stage tongue SCC were analyzed using immunohistochemistry to examine protein expression corresponding to the histopathological definition of tumors and to evaluate prognosis. The aberrant stemness gene expression caused by altered DNA methylation appeared to regulate early‑stage HNSCC characteristics. The results of the present study indicated a correlation between OLFM4 expression and promoter methylation, and suggest that it plays an important role in tumor cell heterogeneity in HNSCC.

References

1 

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar

2 

Patel SS, Shah KA, Shah MJ, Kothari KC and Rawal RM: Cancer stem cells and stemness markers in oral squamous cell carcinomas. Asian Pac J Cancer Prev. 15:8549–8556. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Zhang J, Liu WL, Tang DC, Chen L, Wang M, Pack SD, Zhuang Z and Rodgers GP: Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene. 283:83–93. 2002. View Article : Google Scholar : PubMed/NCBI

4 

Oue N, Sentani K, Noguchi T, Ohara S, Sakamoto N, Hayashi T, Anami K, Motoshita J, Ito M, Tanaka S, et al: Serum olfacto-medin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. Int J Cancer. 125:2383–2392. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Luo Z, Zhang Q, Zhao Z, Li B, Chen J and Wang Y: OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. J Cancer Res Clin Oncol. 137:1713–1720. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Kobayashi D, Koshida S, Moriai R, Tsuji N and Watanabe N: Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci. 98:334–340. 2007. View Article : Google Scholar : PubMed/NCBI

7 

Chen L, Li H, Liu W, Zhu J, Zhao X, Wright E, Cao L, Ding I and Rodgers GP: Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1. Carcinogenesis. 32:986–994. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Li H, Liu W, Chen W, Zhu J, Deng CX and Rodgers GP: Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway. Sci Rep. 5:169742015. View Article : Google Scholar : PubMed/NCBI

9 

Kulkarni NH, Karavanich CA, Atchley WR and Anholt RR: Characterization and differential expression of a human gene family of olfactomedin-related proteins. Genet Res. 76:41–50. 2000. View Article : Google Scholar : PubMed/NCBI

10 

Liu RH, Yang MH, Xiang H, Bao LM, Yang HA, Yue LW, Jiang X, Ang N, Wu LY and Huang Y: Depletion of OLFM4 gene inhibits cell growth and increases sensitization to hydrogen peroxide and tumor necrosis factor-alpha induced-apoptosis in gastric cancer cells. J Biomed Sci. 19:382012. View Article : Google Scholar : PubMed/NCBI

11 

Liu W, Zhu J, Cao L and Rodgers GP: Expression of hGC-1 is correlated with differentiation of gastric carcinoma. Histopathology. 51:157–165. 2007. View Article : Google Scholar : PubMed/NCBI

12 

Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, et al: A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmet-astatic tumor marker. Mol Cell Proteomics. 10:M111.009712. 2011. View Article : Google Scholar

13 

Zhang X, Huang Q, Yang Z, Li Y and Li CY: GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res. 64:2474–2481. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, Tanaka S, Kuniyasu H, Kamata N and Yasui W: Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene. 26:4383–4393. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Sun YW, Chen KM, Imamura Kawasawa Y, Salzberg AC, Cooper TK, Caruso C, Aliaga C, Zhu J, Gowda K, Amin S and El-Bayoumy K: Hypomethylated Fgf3 is a potential biomarker for early detection of oral cancer in mice treated with the tobacco carcinogen dibenzo[def,p]chrysene. PLoS One. 12:e01868732017. View Article : Google Scholar

16 

Umair A, Tarakji B, Ibrahim A, Nasser A, Fq A and Shreen A: Quantitative study of epigenetic signature in head and neck squamous cell carcinoma. Turk J Med Sci. 45:372–386. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN Jr, Frederick MJ, Wang J, Lang W, Feng L, et al: New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila). 8:1027–1035. 2015. View Article : Google Scholar

18 

Bakhtiar SM, Ali A and Barh D: Epigenetics in head and neck cancer. Methods Mol Biol. 1238:751–769. 2015. View Article : Google Scholar

19 

Prawdzic Senkowska A, Kiczmer P, Strzelczyk JK, Kowalski D, Krakowczyk Ł and Ostrowska Z: Impact of HPV infection on gene expression and methylation in oral cancer patients. J Med Microbiol. 68:440–445. 2019. View Article : Google Scholar : PubMed/NCBI

20 

Zhou C, Shen Z, Ye D, Li Q, Deng H, Liu H and Li J: The Association and clinical significance of CDKN2A promoter methylation in head and neck squamous cell carcinoma: A meta-analysis. Cell Physiol Biochem. 50:868–882. 2018. View Article : Google Scholar : PubMed/NCBI

21 

Mydlarz WK, Hennessey PT, Wang H, Carvalho AL and Califano JA: Serum biomarkers for detection of head and neck squamous cell carcinoma. Head Neck. 38:9–14. 2016. View Article : Google Scholar

22 

Shi H, Chen X, Lu C, Gu C, Jiang H, Meng R, Niu X, Huang Y and Lu M: Association between P16INK4a promoter methylation and HNSCC: A meta-analysis of 21 published studies. PLoS One. 10:e01223022015. View Article : Google Scholar : PubMed/NCBI

23 

Zhao J, Shu P, Duan F, Wang X, Min L, Shen Z, Ruan Y, Qin J, Sun Y and Qin X: Loss of OLFM4 promotes tumor migration through inducing interleukin-8 expression and predicts lymph node metastasis in early gastric cancer. Oncogenesis. 5:e2342016. View Article : Google Scholar : PubMed/NCBI

24 

Jang BG, Lee BL and Kim WH: Olfactomedin-related proteins 4 (OLFM4) expression is involved in early gastric carcinogenesis and of prognostic significance in advanced gastric cancer. Virchows Arch. 467:285–294. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Barnes L, Eveson J, Reichart P and Sidransky D: World Health Organization classifications tumours. Pathology and genetics of head and neck tumours Lyon: IARC; 2005

26 

Rangan SR: A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer. 29:117–121. 1972. View Article : Google Scholar : PubMed/NCBI

27 

Peterson WD Jr, Stulberg CS, Swanborg NK and Robinson AR: Glucose-6-phosphate dehydrogenase isoenzymes in human cell cultures determined by sucrose-agar gel and cellulose acetate zymograms. Proc Soc Exp Biol Med. 128:772–776. 1968. View Article : Google Scholar : PubMed/NCBI

28 

Zhou Y and Hu Z: Epigenetic DNA demethylation causes inner ear stem cell differentiation into hair cell-like cells. Front Cell Neurosci. 10:1852016. View Article : Google Scholar : PubMed/NCBI

29 

van der Flier LG, Haegebarth A, Stange DE, van de Wetering M and Clevers H: OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. Gastroenterology. 137:15–17. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Yamazaki H, Mori T, Yazawa M, Maeshima AM, Matsumoto F, Yoshimoto S, Ota Y, Kaneko A, Tsuda H and Kanai Y: Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: Clues for diagnosis. Lab Invest. 93:1331–1338. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Castilho RM, Squarize CH and Almeida LO: Epigenetic modifications and Head and neck cancer: Implications for tumor progression and resistance to therapy. Int J Mol Sci. 18:pii: E1506. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Schuijers J, van der Flier LG, van Es J and Clevers H: Robust cre-mediated recombination in small intestinal stem cells utilizing the olfm4 locus. Stem Cell Reports. 3:234–241. 2014. View Article : Google Scholar : PubMed/NCBI

33 

Ziskin JL, Dunlap D, Yaylaoglu M, Fodor IK, Forrest WF, Patel R, Ge N, Hutchins GG, Pine JK, Quirke P, et al: In situ validation of an intestinal stem cell signature in colorectal cancer. Gut. 62:1012–1023. 2013. View Article : Google Scholar

34 

Liu W, Liu Y, Zhu J, Wright E, Ding I and Rodgers GP: Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma. Clin Cancer Res. 14:1041–1049. 2008. View Article : Google Scholar : PubMed/NCBI

35 

Gersemann M, Becker S, Nuding S, Antoni L, Ott G, Fritz P, Oue N, Yasui W, Wehkamp J and Stange EF: Olfactomedin-4 is a glycoprotein secreted into mucus in active IBD. J Crohns Colitis. 6:425–434. 2012. View Article : Google Scholar : PubMed/NCBI

36 

Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe NA, Srikanth SM, Renuse S, Ahmad S, Radhakrishnan A, Barbhuiya MA, Kumar RV, et al: Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim Biophys Acta. 1834:2308–2316. 2013. View Article : Google Scholar : PubMed/NCBI

37 

Grover PK, Hardingham JE and Cummins AG: Stem cell marker olfactomedin 4: Critical appraisal of its characteristics and role in tumorigenesis. Cancer Metastasis Rev. 29:761–775. 2010. View Article : Google Scholar : PubMed/NCBI

38 

Liu W, Li H, Hong SH, Piszczek GP, Chen W and Rodgers GP: Olfactomedin 4 deletion induces colon adenocarcinoma in ApcMin/+ mice. Oncogene. 35:5237–5247. 2016. View Article : Google Scholar : PubMed/NCBI

39 

Sentani K, Sakamoto N, Shimamoto F, Anami K, Oue N and Yasui W: Expression of olfactomedin 4 and claudin-18 in serrated neoplasia of the colorectum: A characteristic pattern is associated with sessile serrated lesion. Histopathology. 62:1018–1027. 2013. View Article : Google Scholar : PubMed/NCBI

40 

Yamanoi K, Arai E, Tian Y, Takahashi Y, Miyata S, Sasaki H, Chiwaki F, Ichikawa H, Sakamoto H, Kushima R, et al: Epigenetic clustering of gastric carcinomas based on DNA meth-ylation profiles at the precancerous stage: Its correlation with tumor aggressiveness and patient outcome. Carcinogenesis. 36:509–520. 2015. View Article : Google Scholar : PubMed/NCBI

41 

Guo LL, He ZC, Yang CQ, Qiao PT and Yin GL: Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling. BMB Rep. 48:630–635. 2015. View Article : Google Scholar : PubMed/NCBI

42 

Su W, Luo L, Wu F, Lai Z, Li X, Xie Z, Tang Z, Yang Z and Liang R: Low expression of olfactomedin 4 correlates with poor prognosis in smoking patients with non-small cell lung cancer. Hum Pathol. 46:732–738. 2015. View Article : Google Scholar : PubMed/NCBI

43 

Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, Kihara M, Mikami S, Bando Y, Maeda S, et al: Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer. 132:1368–1382. 2013. View Article : Google Scholar

44 

Ogata K, Aihara R, Mochiki E, Ogawa A, Yanai M, Toyomasu Y, Ando H, Ohno T, Asao T and Kuwano H: Clinical significance of melanoma antigen-encoding gene-1 (MAGE-1) expression and its correlation with poor prognosis in differentiated advanced gastric cancer. Ann Surg Oncol. 18:1195–1203. 2011. View Article : Google Scholar

45 

Zhang S, Zhou X, Yu H and Yu Y: Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 10:1632010. View Article : Google Scholar : PubMed/NCBI

46 

Zhou SJ, Zhuo SR, Yang XQ, Qin CX and Wang ZL: Serum Dickkopf-1 expression level positively correlates with a poor prognosis in breast cancer. Diagn Pathol. 9:1612014. View Article : Google Scholar : PubMed/NCBI

47 

Shi Y, Gong HL, Zhou L, Tian J and Wang Y: Dickkopf-1 is a novel prognostic biomarker for laryngeal squamous cell carcinoma. Acta Otolaryngol. 134:753–759. 2014. View Article : Google Scholar : PubMed/NCBI

48 

Dong LL, Qu LY, Chu LY, Zhang XH and Liu YH: Serum level of DKK-1 and its prognostic potential in non-small cell lung cancer. Diagn Pathol. 9:522014. View Article : Google Scholar : PubMed/NCBI

49 

Chen C, Zhou H, Zhang X, Ma X, Liu Z and Liu X: Elevated levels of Dickkopf-1 are associated with β-catenin accumulation and poor prognosis in patients with chondrosarcoma. PLoS One. 9:e1054142014. View Article : Google Scholar

50 

Huang Y, Yang X, Zhao F, Shen Q, Wang Z, Lv X, Hu B, Yu B, Fan J and Qin W: Overexpression of Dickkopf-1 predicts poor prognosis for patients with hepatocellular carcinoma after ortho-topic liver transplantation by promoting cancer metastasis and recurrence. Med Oncol. 31:9662014. View Article : Google Scholar

51 

Tao YM, Liu Z and Liu HL: Dickkopf-1 (DKK1) promotes invasion and metastasis of hepatocellular carcinoma. Dig Liver Dis. 45:251–257. 2013. View Article : Google Scholar

52 

Jiang T, Huang L and Zhang S: DKK-1 in serum as a clinical and prognostic factor in patients with cervical cancer. Int J Biol Markers. 28:221–225. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 55 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Suzuki, T., Yamazaki, H., Honda, K., Ryo, E., Kaneko, A., Ota, Y., & Mori, T. (2019). Altered DNA methylation is associated with aberrant stemness gene expression in early‑stage HNSCC. International Journal of Oncology, 55, 915-924. https://doi.org/10.3892/ijo.2019.4857
MLA
Suzuki, T., Yamazaki, H., Honda, K., Ryo, E., Kaneko, A., Ota, Y., Mori, T."Altered DNA methylation is associated with aberrant stemness gene expression in early‑stage HNSCC". International Journal of Oncology 55.4 (2019): 915-924.
Chicago
Suzuki, T., Yamazaki, H., Honda, K., Ryo, E., Kaneko, A., Ota, Y., Mori, T."Altered DNA methylation is associated with aberrant stemness gene expression in early‑stage HNSCC". International Journal of Oncology 55, no. 4 (2019): 915-924. https://doi.org/10.3892/ijo.2019.4857